

Peer Reviews
Hear the Difference Bravecto® is Making
Across the country and beyond, veterinarians like yourself are discovering the difference 12-week* flea and tick protection with Bravecto (fluralaner) makes for dogs, cats and their clinic.
Watch their stories to hear how.

Dr. Cathy Lund
Rhode Island
“The safety profile of Bravecto provides confidence, and the long-lasting efficacy addresses flea infestations in the cat’s home.”

Dr. Craig Prior
Tennessee
“Bravecto goes a long way in solving clients’ flea and tick problems, so they’ll keep coming back to the clinic.”

Dr. Dan Markwalder
Illinois
“Bravecto is a popular choice among pet owners and the compliance numbers back it up.”

Dr. Don Costlow
New York
“The 12-week* protection of Bravecto provides less stress and less complications for pet owners.”

Dr. John Issacs
North Carolina
“The benefits of Bravecto’s proven safety and long-lasting efficacy against infestations for dogs and cats.”

Dr. Michael Norris
New Hampshire
“The efficacious long-lasting protection of Bravecto helps make training and inventory easy.”

Dr. Paul Ulrich
California
“The benefits of highly effective and easy-to-apply 12-week* protection for cats.”

Dr. Randal Bennett
Texas
“Bravecto gives pet owners the joy of a flea and tick-free household.”

Dr. Sandy Merchant
Louisiana
“Bravecto is easy to offer to clients and administer, making pet owners happy.”
No items to show.
See What Your Peers and Pet Owners are Saying About the Difference of Bravecto
CONTACT US ABOUT THE 12-WEEK* DIFFERENCE
Contact us for more information about Bravecto for your hospital.
We’ll answer any questions, and help you start prescribing Bravecto for the dogs and cats in your care.


For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
This site is intended for veterinary professionals. Visit our website for pet parents.
*BRAVECTO kills fleas and prevents flea infestation. Bravecto Chew and Bravecto Topical for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. Bravecto Topical for Cats kills ticks (black-legged tick) for 12 weeks and American dog ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION:
The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age. For topical use only. Avoid oral ingestion. The safety of BRAVECTO PLUS has not been established in breeding, pregnant and lactating cats. Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. Use with caution in cats that are heartworm positive. The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated.
References:
1. Bravecto Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014.
2. Bravecto Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2016.
3. Bravecto Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016.
4. Freedom of Information Summary, NADA 141-426. Approved May 15, 2014.
5. Freedom of Information Summary, NADA 141-459. Approved 2016. 6. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasites & Vectors (2014) 7:87.
7. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) collies after oral administration. Parasites & Vectors (2014) 7:86.
8. Burgio et al. Parasites & Vectors (2016) 9:626.
9. Taenzler et al. Parasites & Vectors (2014) 7:567.
10. Wengenmayer et al. Parasites & Vectors (2014) 7:525.